{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:54:33Z","timestamp":1793390073896,"version":"4.5.0"},"reference-count":330,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.pharmthera.2007.10.001","type":"journal-article","created":{"date-parts":[[2007,11,14]],"date-time":"2007-11-14T22:04:10Z","timestamp":1195077850000},"page":"244-279","source":"Crossref","is-referenced-by-count":1364,"title":["Tumor necrosis factor antagonist mechanisms of action: A comprehensive review"],"prefix":"10.1016","volume":"117","author":[{"given":"Daniel","family":"Tracey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Klareskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Sasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen G.","family":"Salfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul P.","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2007.10.001_bib1","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/ard.2003.012617","article-title":"Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: a time kinetic study","volume":"63","author":"Agarwal","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib2","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard.2003.014647","article-title":"Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy infliximab in rheumatoid arthritis is associated with clinical improvement","volume":"63","author":"Alessandri","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib3","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1002\/eji.1830271018","article-title":"A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55\/p75 TNF receptor signaling","volume":"27","author":"Alexopoulou","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1084\/jem.188.4.745","article-title":"Complementation of lymphotoxin alpha knockout mice with tumor necrosis factor-expressing transgenes rectifies defective splenic structure and function","volume":"188","author":"Alexopoulou","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri1786","article-title":"Lymphoid neogenesis in chronic inflammatory diseases","volume":"6","author":"Aloisi","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-3083.1999.00458.x","article-title":"Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers","volume":"49","author":"Alsalameh","year":"1999","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semarthrit.2005.01.005","article-title":"Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles","volume":"34","author":"Anderson","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib8","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1126\/science.1075958","article-title":"Projection of an immunological self shadow within the thymus by the Aire protein","volume":"298","author":"Anderson","year":"2002","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.pharmthera.2007.10.001_bib9","first-page":"S677","article-title":"Anti-tumor necrosis factor therapy in rheumatoid arthritis alters B lymphocyte dynamics","volume":"52","author":"Anolik","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.1780330302","article-title":"Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis","volume":"33","author":"Arend","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib11","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","article-title":"Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study","volume":"50","author":"Aringer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib12","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/ard.2005.045872","article-title":"Swedish registers to examine drug safety and clinical issues in RA","volume":"65","author":"Askling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib14","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib17","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/ar1851","article-title":"Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study","volume":"8","author":"Atzeni","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2004.08.004","article-title":"Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review","volume":"4","author":"Atzeni","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1196\/annals.1361.100","article-title":"Autoimmunity and anti-TNF-\u03b1 agents","volume":"1051","author":"Atzeni","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00002281-200405000-00014","article-title":"Rheumatoid arthritis and malignant lymphomas","volume":"16","author":"Baecklund","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/431405a","article-title":"Cancer: an inflammatory link","volume":"431","author":"Balkwill","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00063030-200418020-00005","article-title":"Adalimumab: a review of its use in rheumatoid arthritis","volume":"18","author":"Bang","year":"2004","journal-title":"Biodrugs"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0092-8674(93)90132-A","article-title":"Crystal structure of the soluble human 55\u00a0kd TNF receptor-human TNF beta complex: implications for TNF receptor activation","volume":"73","author":"Banner","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib25","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/ard.60.7.660","article-title":"Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF-alpha in patients with rheumatoid arthritis","volume":"60","author":"Barrera","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/ard.62.9.825","article-title":"Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis","volume":"62","author":"Barrera","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib27","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: the relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib28","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/j.1440-1746.2005.03848.x","article-title":"Successful treatment with adalimumab in infliximab-resistant Crohn's disease","volume":"20","author":"Barthel","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib29","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib31","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJM199606273342607","article-title":"The tumor necrosis factor ligand and receptor families","volume":"334","author":"Bazzoni","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib32","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO;2-M","article-title":"Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis","volume":"43","author":"Bendele","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1398-9995.1984.tb01941.x","article-title":"Antibodies against nuclear components in schistosomiasis. Results compared to values in patients with rheumatoid arthritis, systemic lupus erythematosus, and osteoarthrosis","volume":"39","author":"Bendixen","year":"1984","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib34","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor \u03b1 inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib35","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.clnu.2004.07.016","article-title":"Acute and \u201cchronic\u201d phase reaction: a mother of disease","volume":"23","author":"Bengmark","year":"2004","journal-title":"Clin Nutr"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/ard.60.2.133","article-title":"Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors","volume":"60","author":"Berg","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib37","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa050580","article-title":"Evidence of a role of tumor necrosis factor alpha in refractory asthma","volume":"354","author":"Berry","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.rdc.2004.01.003","article-title":"Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments","volume":"30","author":"Bieber","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib39","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/gut.44.5.643","article-title":"Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue","volume":"44","author":"Bischoff","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib40","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/rheumatology\/kem091","article-title":"Effectiveness of adalimumab in rheumatoid arthritis in patients with a history of TNF antagonists in clinical practice","volume":"46","author":"Bombardieri","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib41","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2302\/kjm.54.127","article-title":"TNF\u03b1 and pathologic bone resorption","volume":"54","author":"Boyce","year":"2005","journal-title":"Keio J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib44","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/rheumatology\/36.6.643","article-title":"Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha cA2 therapy","volume":"36","author":"Brennan","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis","volume":"2","author":"Brennan","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib48","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.immuni.2005.10.002","article-title":"Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function","volume":"23","author":"Browning","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4049\/jimmunol.154.1.33","article-title":"Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors","volume":"154","author":"Browning","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib47","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.4049\/jimmunol.159.7.3288","article-title":"Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes","volume":"159","author":"Browning","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib49","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/art.21353","article-title":"Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis","volume":"52","author":"Bryl","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib51","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1067\/mai.2000.111307","article-title":"Pathophysiology of severe asthma","volume":"106","author":"Busse","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib50","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1056\/NEJM200102013440507","article-title":"Asthma","volume":"344","author":"Busse","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib52","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.4049\/jimmunol.159.6.2867","article-title":"DBA\/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition","volume":"159","author":"Butler","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib53","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1182\/blood-2006-08-037192","article-title":"The mitochondrial effects of novel apoptogenic molecules generated by psoralen photolysis as a crucial mechanism in PUVA therapy","volume":"109","author":"Caffieri","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib54","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/immu.200390024","article-title":"Isolation and functional characterization of regulatory T cells from the target organ of patients with rheumatoid arthritis","volume":"33","author":"Cao","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib55","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib56","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","article-title":"Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER","volume":"8","author":"Carmona","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00148581-200406030-00001","article-title":"Biologic agents for the treatment of juvenile rheumatoid arthritis: current status","volume":"6","author":"Carrasco","year":"2004","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib60","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/art.21528","article-title":"Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis","volume":"54","author":"Catrina","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib58","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/rheumatology\/41.5.484","article-title":"Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis","volume":"41","author":"Catrina","year":"2002","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2007.10.001_bib59","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/art.20764","article-title":"Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report","volume":"52","author":"Catrina","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib61","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1126\/science.288.5475.2351","article-title":"A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling","volume":"288","author":"Chan","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib62","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis","volume":"163","author":"Charles","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib63","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.pharmthera.2007.10.001_bib64","first-page":"A696","article-title":"Anti-TNF antibody induced stimulated T lymphocyte apoptosis depends on the concentration of the antibody and etanercept induces apoptosis at rates equivalent to infliximab and adalimumab at 10\u00a0micrograms per ml concentration","volume":"130","author":"Chaudhary","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/ard.2005.038851","article-title":"The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis","volume":"65","author":"Chen","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib66","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ni982","article-title":"Lymphotoxin pathway directs thymic Aire expression","volume":"4","author":"Chin","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib67","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.4049\/jimmunol.171.5.2262","article-title":"TNF skews monocyte differentiation from macrophages to dendritic cells","volume":"171","author":"Chomarat","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib68","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib69","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1073\/pnas.93.9.3967","article-title":"CNI-1493 inhibits monocyte\/macrophage tumor necrosis factor by suppression of translation efficiency","volume":"93","author":"Cohen","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib70","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI117394","article-title":"Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor\/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis","volume":"94","author":"Cope","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib71","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1740-2557-3-5","article-title":"Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha","volume":"3","author":"Cordiali-Fei","year":"2006","journal-title":"J Autoimmune Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib72","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.57.2.3","article-title":"Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis","volume":"57","author":"Cronstein","year":"2005","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib73","first-page":"2319","article-title":"Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis","volume":"30","author":"Crotti","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib74","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.8171323","article-title":"A lymphotoxin-beta-specific receptor","volume":"264","author":"Crowe","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib75","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0002-9440(10)62346-2","article-title":"Caveolae participate in tumor necrosis factor receptor 1 signaling and internalization in a human endothelial cell line","volume":"166","author":"D'Alessio","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib76","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.61.10.916","article-title":"Synovial macrophage-osteoclast differentiation in inflammatory arthritis","volume":"61","author":"Danks","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib77","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2796.2003.01298.x","article-title":"Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies","volume":"255","author":"D'Auria","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib78","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/art.21190","article-title":"Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis","volume":"52","author":"de Rycke","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib79","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/ard.61.4.311","article-title":"Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation","volume":"61","author":"den Broeder","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib80","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/gut.53.1.70","article-title":"Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease","volume":"53","author":"Di Sabatino","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib81","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","article-title":"Dickkopf-1 is a master regulator of joint remodeling","volume":"13","author":"Diarra","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib82","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib83","first-page":"192","article-title":"Pentoxifylline suppression of tumor necrosis factor gene transcription","volume":"110","author":"Doherty","year":"1991","journal-title":"Surgery"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib84","first-page":"1029","article-title":"Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis","volume":"146","author":"Dvorak","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib85","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1002\/art.22077","article-title":"Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor?","volume":"54","author":"Edwards","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib86","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.4049\/jimmunol.170.10.5210","article-title":"The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes","volume":"170","author":"Ehlers","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib87","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib88","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.4049\/jimmunol.164.12.6193","article-title":"Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages","volume":"164","author":"Eissner","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib89","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cytogfr.2004.03.011","article-title":"Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system","volume":"15","author":"Eissner","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib90","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/j.semarthrit.2003.10.003","article-title":"The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Elkayam","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib91","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib92","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib93","series-title":"Immunex Corporation, Thousand Oaks, CA","author":"Enbrel (etanercept) prescribing information.","year":"2007"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib94","doi-asserted-by":"crossref","first-page":"14497","DOI":"10.1016\/S0021-9258(18)77330-4","article-title":"Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity","volume":"265","author":"Engelmann","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib95","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0002-9440(10)63262-2","article-title":"Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection","volume":"165","author":"Engwerda","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib96","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1084\/jem.180.6.2173","article-title":"Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis","volume":"180","author":"Evans","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib97","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4049\/jimmunol.171.1.115","article-title":"A role for the lymphotoxin\/LIGHT axis in the pathogenesis of murine collagen-induced arthritis","volume":"171","author":"Fava","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib98","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nri802","article-title":"Development of anti-TNF therapy for rheumatoid arthritis","volume":"2","author":"Feldmann","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib99","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?","volume":"19","author":"Feldmann","year":"2001","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1297-319X(01)00335-9","article-title":"Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies","volume":"69","author":"Feldmann","year":"2002","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib101","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nm939","article-title":"Lasker Clinical Medical Research Award: TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases","volume":"9","author":"Feldmann","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib102","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature03727","article-title":"Design of effective immunotherapy for human autoimmunity","volume":"435","author":"Feldmann","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib103","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/030097401316909585","article-title":"Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis","volume":"30","author":"Feuerherm","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib104","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/ard.2005.045062","article-title":"Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis","volume":"65","author":"Finckh","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib105","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJM199606273342603","article-title":"Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein","volume":"334","author":"Fisher","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib106","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","article-title":"Tumor necrosis factor-[alpha] is required in the protective immune response against mycobacterium tuberculosis in mice","volume":"2","author":"Flynn","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib107","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.14309\/00000434-200509001-00807","article-title":"In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870)","volume":"100","author":"Fossati","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib108","doi-asserted-by":"crossref","first-page":"S298","DOI":"10.14309\/00000434-200509001-00806","article-title":"Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes","volume":"100","author":"Fossati","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib109","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/1529-0131(200109)44:9<2024::AID-ART351>3.0.CO;2-K","article-title":"Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis","volume":"44","author":"Fraser","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib110","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ncb1440","article-title":"SPPL2a and SPPL2b promote intramembrane proteolysis of TNF[alpha] in activated dendritic cells to trigger IL-12 production","volume":"8","author":"Friedmann","year":"2006","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib111","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev.immunol.17.1.399","article-title":"Development and maturation of secondary lymphoid tissues","volume":"17","author":"Fu","year":"1999","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib112","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.2007.081430","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007","volume":"66","author":"Furst","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib113","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","article-title":"Tumor necrosis factor antagonists: different kinetics and\/or mechanisms of action may explain differences in the risk for developing granulomatous infection","volume":"36","author":"Furst","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib114","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1517\/14712598.4.12.1963","article-title":"Thalidomide-derived immunomodulatory drugs as therapeutic agents","volume":"4","author":"Galustian","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib115","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1517\/14712598.5.12.1593","article-title":"Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs","volume":"5","author":"Gelderman","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib116","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1172\/JCI2676","article-title":"Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells","volume":"102","author":"Genestier","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib117","first-page":"S451","article-title":"The relationship of radiographic progression to clinical response in patients with early RA treated with adalimumab (Humira\u00ae) plus MTX or MTX alone","volume":"52","author":"Genovese","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib340","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/art.21896","article-title":"The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction","volume":"54","author":"Geusens","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib119","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/ard.2003.018085","article-title":"Early effects of tumour necrosis factor {alpha} blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis","volume":"63","author":"Goedkoop","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib118","doi-asserted-by":"crossref","first-page":"R326","DOI":"10.1186\/ar1182","article-title":"Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study","volume":"6","author":"Goedkoop","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib120","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib121","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nri1151","article-title":"Lymphotoxin\/light, lymphoid microenvironments and autoimmune disease","volume":"3","author":"Gommerman","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib122","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2133.2005.06816.x","article-title":"The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques","volume":"153","author":"Gordon","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib123","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib125","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.175.4.2721","article-title":"TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques","volume":"175","author":"Gottlieb","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib124","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.pharmthera.2007.10.001_bib126","first-page":"A697","article-title":"Neutralization of soluble and membrane tumor necrosis factor-alpha (TNF- alpha) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-alpha receptor-specific bioassays","volume":"130","author":"Gramlick","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib127","first-page":"S140","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) relationships of adalimumab (HUMIRA, Abbott) in rheumatoid arthritis (RA) patients during phase II\/III clinical trials","volume":"48","author":"Granneman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib128","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80\u00a0kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib129","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1073\/pnas.95.2.570","article-title":"The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor","volume":"95","author":"Grell","year":"1998","journal-title":"PNAS"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jnci\/85.4.307","article-title":"Incidence of cancer among patients with rheumatoid arthritis","volume":"85","author":"Gridley","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib131","first-page":"93","article-title":"Distinct and nonredundant in vivo functions of TNF produced by T cells and macrophages\/neutrophils: protective and deleterious effects","volume":"22","author":"Grivennikov","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib132","first-page":"118","article-title":"TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis","volume":"22","author":"Gudbrandsdottir","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib133","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1084\/jem.171.2.465","article-title":"Endotoxin-responsive sequences control cachectin\/tumor necrosis factor biosynthesis at the translational level [published erratum appears in J Exp Med 171(3), 971\u2013972]","volume":"171","author":"Han","year":"1990","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib134","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1002\/art.21341","article-title":"Blockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 response","volume":"52","author":"Han","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib135","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib136","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.semarthrit.2005.01.003","article-title":"Differentiating the efficacy of the tumor necrosis factor inhibitors","volume":"34","author":"Haraoui","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib137","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4049\/jimmunol.166.1.130","article-title":"Outside-to-inside signal through the membraneTNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells","volume":"166","author":"Harashima","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib138","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/rheumatology\/keg047","article-title":"Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls","volume":"42","author":"Haynes","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2005.02143.x","article-title":"The intriguing biology of the tumour necrosis factor\/tumour necrosis factor receptor superfamily: players, rules and the games","volume":"115","author":"Hehlgans","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib140","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.4049\/jimmunol.152.7.3550","article-title":"TNF induces internalization of the p60 receptor and shedding of the p80 receptor","volume":"152","author":"Higuchi","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib141","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/thx.2005.045260","article-title":"Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma","volume":"60","author":"Howarth","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib142","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.4049\/jimmunol.161.11.5937","article-title":"TNF\/lymphotoxin-alpha double-mutant mice resist septic arthritis but display increased mortality in response to Staphylococcus aureus","volume":"161","author":"Hultgren","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib143","series-title":"Abbott Laboratories, North Chicago, IL","year":"2007"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib144","first-page":"3","article-title":"Immunogenicity of engineered antibodies","volume":"vol. 36","author":"Hwang","year":"2005"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib145","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1073\/pnas.96.11.6336","article-title":"Requirement for membrane lymphotoxin in natural killer cell development","volume":"96","author":"Iizuka","year":"1999","journal-title":"PNAS"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib146","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.4049\/jimmunol.166.9.5495","article-title":"Prolonged exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR\/CD3 complex at the cell surface","volume":"166","author":"Isomaki","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib147","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.4049\/jimmunol.163.5.2809","article-title":"Mice with a targeted mutation in lymphotoxin-alpha exhibit enhanced tumor growth and metastasis: impaired NK cell development and recruitment","volume":"163","author":"Ito","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib148","first-page":"373","article-title":"Towards a network theory of the immune system","volume":"125C","author":"Jerne","year":"1974","journal-title":"Ann Immunol (Paris)"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib149","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.4049\/jimmunol.163.9.5049","article-title":"IL-1a\u03b2 blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-\u00e1 blockade only ameliorates joint inflammation","volume":"163","author":"Joosten","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib150","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.160.7.3513","article-title":"IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1\u03b2 and TNF-a, by human macrophages","volume":"160","author":"Jovanovic","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib151","first-page":"272","article-title":"Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab","volume":"34","author":"Kaine","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib152","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib153","first-page":"S132","article-title":"Treatment with adalimumab (D2E7) does not affect normal immune responsiveness","volume":"46","author":"Kavanaugh","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib154","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.bor.0000231901.19795.8a","article-title":"Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis","volume":"18","author":"Kavanaugh","year":"2006","journal-title":"Curr Opin Rheumatol"},{"issue":"Suppl 2123","key":"10.1016\/j.pharmthera.2007.10.001_bib155","first-page":"S833","article-title":"One-year results of golimumab compared with placebo in patients with active RA despite treatment with methotrexate: a phase II, randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Kay","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2007.10.001_bib156","first-page":"136","article-title":"Murine model for assessing adalimumab, infliximab, and etanercept to prevent polyarthritis","volume":"62","author":"Kaymakcalan","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"Suppl II","key":"10.1016\/j.pharmthera.2007.10.001_bib157","first-page":"458","article-title":"Adalimumab, etanercept, and infliximab bind to soluble and transmembrane TNF with similar affinities","volume":"65","author":"Kaymakcalan","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"Suppl II","key":"10.1016\/j.pharmthera.2007.10.001_bib158","first-page":"458","article-title":"Differential TNF-neutralizing potencies of adalimumab, etanercept, and infliximab","volume":"65","author":"Kaymakcalan","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib159","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib160","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/rheumatology\/keh617","article-title":"Safety of biologic therapies: an update","volume":"32","author":"Keystone","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib161","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab a human anti-tumor necrosis factor monoclonal antibody in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib162","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.4049\/jimmunol.173.7.4500","article-title":"Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28","volume":"173","author":"Kim","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib163","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cyto.2004.06.008","article-title":"Effect of different tumor necrosis factor TNF reactive agents on reverse signaling of membrane integrated TNF in monocytes","volume":"28","author":"Kirchner","year":"2004","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib164","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1172\/JCI26132","article-title":"M-CSF mediates TNF-induced inflammatory osteolysis","volume":"115","author":"Kitaura","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib165","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0952-7915(99)00033-3","article-title":"Rheumatoid arthritis and its animal models: the role of TNF-[alpha] and the possible absence of specific immune reactions","volume":"11","author":"Klareskog","year":"1999","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib166","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib167","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterization of a mouse-human chimeric anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Mol Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib168","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/ard.62.suppl_2.ii60","article-title":"Angiogenesis as a target in rheumatoid arthritis","volume":"62","author":"Koch","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib169","doi-asserted-by":"crossref","first-page":"iii29","DOI":"10.1136\/ard.2006.058529","article-title":"Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis","volume":"65","author":"Koenders","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.pharmthera.2007.10.001_bib170","first-page":"A111","article-title":"Differences in Fc receptor and C1q binding in tumor necrosis factor (TNF) antagonists may contribute to differences in mechanisms of action","volume":"124","author":"Kohno","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.pharmthera.2007.10.001_bib171","first-page":"S562","article-title":"Adalimumab and infliximab bind to Fc-receptor and C1q and generate immunoprecipitation: a different mechanism from etanercept","volume":"52","author":"Kohno","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib172","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semarthrit.2005.01.002","article-title":"TNF pathophysiology in murine models of chronic inflammation and autoimmunity","volume":"34","author":"Kollias","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib173","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000060546","article-title":"The role of TNF\/TNFR in organ-specific and systemic autoimmunity: implications for the design of optimized 'anti-TNF' therapies","volume":"5","author":"Kollias","year":"2002","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib174","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1074-7613(00)80038-2","article-title":"Impaired on\/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies","volume":"10","author":"Kontoyiannis","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib175","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/ard.61.8.704","article-title":"Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines","volume":"61","author":"Koshy","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib176","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/1529-0131(200105)44:5<1003::AID-ANR179>3.3.CO;2-R","article-title":"Activated human T cells directly induce osteoclastogenesis from human monocytes","volume":"44","author":"Kotake","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib177","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/1529-0131(200007)43:7<1488::AID-ANR11>3.0.CO;2-G","article-title":"Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients","volume":"43","author":"Kraan","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib178","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/1529-0131(200008)43:8<1820::AID-ANR18>3.0.CO;2-D","article-title":"Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers","volume":"43","author":"Kraan","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib179","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1084\/jem.183.4.1461","article-title":"Chronic inflammation caused by lymphotoxin is lymphoid neogenesis","volume":"183","author":"Kratz","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib180","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2249.1993.tb03457.x","article-title":"Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor","volume":"94","author":"Kristensen","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib181","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2133.2005.07078.x","article-title":"Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis","volume":"154","author":"Kruger-Krasagakis","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib182","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1002\/art.21426","article-title":"Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies","volume":"52","author":"Kruithof","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib183","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/archsurg.133.5.558","article-title":"Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation","volume":"133","author":"Ksontini","year":"1998","journal-title":"Arch Surg"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib184","first-page":"426","article-title":"Tumor necrosis factor-\u00e1 promotes the expression of ostoprotegrin in rheumatoid synovial fibroblasts","volume":"31","author":"Kubota","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib185","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","article-title":"Effectiveness of TNF-\u00e1 blockade with infliximab in refractory Wegener's granulomatosis","volume":"41","author":"Lamprecht","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib186","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1002\/art.22143","article-title":"Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes","volume":"54","author":"Landew\u00e9","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib187","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/ard.2004.026120","article-title":"Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis","volume":"64","author":"Lange","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib188","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1002\/art.20637","article-title":"Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappa-B, osteoprotegerin, and receptor activator of nuclear factor kappa-B ligand","volume":"50","author":"Lee","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib189","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/14750708.2.1.13","article-title":"Adalimumab for the treatment of rheumatoid arthritis","volume":"2","author":"Lee","year":"2005","journal-title":"Therapy"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib190","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1074-7613(03)00092-X","article-title":"Recruitment of TNF receptor 1 to lipid rafts is essential for TNF[alpha]-mediated NF-[kappa]B activation","volume":"18","author":"Legler","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib191","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib192","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1128\/MCB.01751-05","article-title":"Novel lymphotoxin alpha (LTalpha) knockout mice with unperturbed tumor necrosis factor expression: reassessing LTalpha biological functions","volume":"26","author":"Liepinsh","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib193","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1172\/JCI31537","article-title":"A cytokine-mediated link between innate immunity, inflammation, and cancer","volume":"117","author":"Lin","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib194","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"New Engl J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib195","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib196","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"Lobo","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib197","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.4049\/jimmunol.156.4.1646","article-title":"In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis short term cellular and molecular effects","volume":"156","author":"Lorenz","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib198","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","article-title":"Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway","volume":"121","author":"Lugering","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib199","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4049\/jimmunol.169.1.424","article-title":"Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis","volume":"169","author":"Luther","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib200","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1186\/ar549","article-title":"How does infliximab work in rheumatoid arthritis?","volume":"4","author":"Maini","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib201","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib203","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2007.10.001_bib202","doi-asserted-by":"crossref","first-page":"I56","DOI":"10.1136\/ard.58.2008.i56","article-title":"Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis","volume":"58","author":"Maini","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib204","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jaad.2006.05.004","article-title":"Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients","volume":"55","author":"Malaviya","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib205","first-page":"890","article-title":"Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis","volume":"5","author":"Malaviya","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib206","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.tp.0000231356.57576.82","article-title":"Endothelial cell-T lymphocyte interactions: iP-10 stimulates rapid transendothelial migration of human effector but not central memory CD4+T cells. Requirements for shear stress and adhesion molecules","volume":"82","author":"Manes","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib207","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4049\/jimmunol.175.2.917","article-title":"IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa and calcium signaling","volume":"175","author":"Mangashetti","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib208","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaad.2006.01.038","article-title":"Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy","volume":"54","author":"Markham","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib209","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/1529-0131(199910)42:10<2166::AID-ANR18>3.0.CO;2-K","article-title":"Treatment with monoclonal anti-tumor necrosis factor \u03b1 antibody results in an accumulation of Th1 CD4+T cells in the peripheral blood of patients with rheumatoid arthritis","volume":"42","author":"Maurice","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib210","first-page":"M55","article-title":"The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance","volume":"1470","author":"Mayo","year":"2000","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 3","key":"10.1016\/j.pharmthera.2007.10.001_bib211","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1186\/ar570","article-title":"Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha\/beta in immunity and autoimmunity","volume":"4","author":"McDevitt","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib212","first-page":"1356","article-title":"Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept","volume":"31","author":"Mease","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib213","doi-asserted-by":"crossref","first-page":"9778","DOI":"10.1074\/jbc.271.16.9778","article-title":"Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects","volume":"271","author":"Medvedev","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib214","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0092-8674(03)00521-X","article-title":"Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes","volume":"114","author":"Micheau","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib215","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1053\/j.gastro.2004.01.036","article-title":"Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha","volume":"26","author":"Mitoma","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib216","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.gastro.2004.11.060","article-title":"Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-[945]","volume":"128","author":"Mitoma","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib217","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4049\/jimmunol.151.3.1548","article-title":"Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists","volume":"151","author":"Mohler","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib218","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/cimm.1996.0179","article-title":"Membrane form of TNFalpha induces both cell lysis and apoptosis in susceptible target cells","volume":"171","author":"Monastra","year":"1996","journal-title":"Cell Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib219","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/1529-0131(200003)43:3<656::AID-ANR23>3.0.CO;2-H","article-title":"Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis","volume":"43","author":"Montesinos","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib220","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/10552","article-title":"Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis","volume":"5","author":"Moore","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib221","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib222","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib223","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/clim.2001.5183","article-title":"Immune function in patients with rheumatoid arthritis treated with etanercept","volume":"103","author":"Moreland","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib224","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2249.2005.02754.x","article-title":"CD4+CD25+T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis","volume":"140","author":"M\u00f6tt\u00f6nen","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib225","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/art.20863","article-title":"Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor","volume":"52","author":"Mueller","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib226","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/sj.cdd.4400374","article-title":"Expression of the lymphotoxin beta receptor on follicular stromal cells in human lymphoid tissues","volume":"5","author":"Murphy","year":"1998","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib227","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1365-2249.1997.3181214.x","article-title":"Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA)","volume":"107","author":"Mussener","year":"1997","journal-title":"Clin Exp Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.pharmthera.2007.10.001_bib228","first-page":"S420","article-title":"Comparison of certolizumab pegol, etanercept, adalimumab, and infliximab: effect on lipopolysaccharide-induced cytokine production by human peripheral blood monocytes","volume":"101","author":"Nesbitt","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib229","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semarthrit.2005.01.004","article-title":"Clinical pharmacokinetics of TNF antagonists: how do they differ?","volume":"34","author":"Nestorov","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib230","first-page":"13","article-title":"Clinical pharmacokinetics of tumor necrosis factor antagonists","volume":"74","author":"Nestorov","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib231","first-page":"129","article-title":"Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis","volume":"138","author":"Nickoloff","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib232","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/ard.2005.039099","article-title":"Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study","volume":"65","author":"Nikas","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib233","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1034\/j.1600-065X.2003.00063.x","article-title":"Organogenesis of peripheral lymphoid organs","volume":"195","author":"Nishikawa","year":"2003","journal-title":"Immunol Rev"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib234","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/ard.2003.008458","article-title":"Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor \u00e1, interleukin 1, and receptor activator of nuclear factor \u03baB ligand (RANKL) regulate osteoclasts","volume":"63","author":"O'Gradaigh","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib235","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/art.1780390703","article-title":"Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis","volume":"39","author":"Paleolog","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib236","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1","article-title":"Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis","volume":"41","author":"Paleolog","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib237","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1074\/jbc.M510160200","article-title":"Inhibition of hormone and cytokine-stimulated ostoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway","volume":"281","author":"Palmqvist","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib238","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1084\/jem.184.4.1397","article-title":"Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response","volume":"184","author":"Pasparakis","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib239","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1073\/pnas.94.12.6319","article-title":"Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor","volume":"94","author":"Pasparakis","year":"1997","journal-title":"PNAS"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib240","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.drudis.2006.06.002","article-title":"Modulating TNF-alpha signaling with natural products","volume":"11","author":"Paul","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib241","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/rheumatology\/kel045","article-title":"RANKL protein is expressed at the pannus\u2013bone interface at sites of articular bone erosion in rheumatoid arthritis","volume":"45","author":"Petit","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib242","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature02924","article-title":"NF-kappaB functions as a tumour promoter in inflammation-associated cancer","volume":"431","author":"Pikarsky","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib243","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/ard.61.8.723","article-title":"Anti-tumour necrosis factor (TNF) {alpha} treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13","volume":"61","author":"Pittoni","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib244","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0161-5890(02)00036-6","article-title":"Recognition of immunoglobulins by Fcgamma receptors","volume":"38","author":"Radaev","year":"2002","journal-title":"Mol Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib245","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.10097","article-title":"Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin","volume":"46","author":"Redlich","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib246","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1172\/JCI0215582","article-title":"Osteoclasts are essential for TNF-alpha-mediated joint destruction","volume":"110","author":"Redlich","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib247","series-title":"Centocor, Inc. Malvern, PA","author":"Remicade (infliximab) prescribing information.","year":"2006"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib248","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1084\/jem.184.5.1999","article-title":"Surface lymphotoxin alpha\/beta complex is required for the development of peripheral lymphoid organs","volume":"184","author":"Rennert","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib249","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1172\/JCI200316069","article-title":"Mechanisms of TNF-a- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis","volume":"111","author":"Ritchlin","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib250","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1084\/jem.193.2.239","article-title":"Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection","volume":"193","author":"Roach","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib251","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/364798a0","article-title":"Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes","volume":"364","author":"Rothe","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib252","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/art.1780360408","article-title":"Soluble tumor necrosis factor receptors in human inflammatory synovial fluids","volume":"36","author":"Roux-Lombard","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib253","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib254","first-page":"S57","article-title":"Generation of fully human anti-TNF antibody D2E7","volume":"41","author":"Salfeld","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib255","first-page":"10","article-title":"New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"5","author":"Sandborn","year":"2005","journal-title":"Rev Gastroenterol Disord"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib256","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib257","first-page":"S10","article-title":"Why do anti-tumor necrosis factor antibodies work in Crohn's disease?","volume":"4","author":"Sands","year":"2004","journal-title":"Rev Gastroenterol Disord"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib258","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/abio.2001.5380","article-title":"Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore","volume":"299","author":"Santora","year":"2001","journal-title":"Anal Biochem"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib259","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.4049\/jimmunol.140.9.3098","article-title":"Antigenic specificities of human monoclonal and polyclonal IgM rheumatoid factors. The C\u03b32-C\u03b33 interface region contains the major determinants","volume":"40","author":"Sasso","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib260","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/art.1780310816","article-title":"Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum","volume":"31","author":"Saxne","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib261","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib262","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib263","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ncprheum0036","article-title":"Mechanisms of disease: the link between RANKL and arthritic bone disease","volume":"1","author":"Schett","year":"2005","journal-title":"Nat Clin Practice Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib264","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s10354-005-0244-7","article-title":"Rheumatoid arthritis: inflammation and bone loss","volume":"156","author":"Schett","year":"2006","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib265","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib266","first-page":"92","article-title":"The efficacy and safety of abatacept or infliximab in RA patients with an inadequate response to MTX: results from a 1-year double-blind, randomized, placebo-controlled trial","volume":"54","author":"Schiff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib267","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1074-7613(04)00234-1","article-title":"Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles","volume":"21","author":"Schneider-Brachert","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib268","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.0906-6705.2004.00205.x","article-title":"Biology of tumor necrosis factor-alpha-implications for psoriasis","volume":"13","author":"Schottelius","year":"2004","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib269","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol CDP870 for treatment of Crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib270","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1074-7613(03)00171-7","article-title":"TNF\/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection","volume":"19","author":"Serbina","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib271","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2036.2005.02309.x","article-title":"Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept","volume":"21","author":"Shen","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib272","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.MIB.0000194185.69800.07","article-title":"Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model","volume":"12","author":"Shen","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib273","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/art.11098","article-title":"Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue","volume":"48","author":"Smeets","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib274","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.20982","article-title":"Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study","volume":"52","author":"Smolen","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib275","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib276","doi-asserted-by":"crossref","first-page":"721","DOI":"10.4049\/jimmunol.176.2.721","article-title":"Cutting edge: tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation","volume":"176","author":"Smookler","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib277","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.4049\/jimmunol.163.3.1350","article-title":"Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice","volume":"163","author":"Smyth","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib278","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"St. Clair","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib279","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St. Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib280","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/art.21946","article-title":"Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinflammatory action","volume":"54","author":"Straub","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib281","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.4049\/jimmunol.155.10.5038","article-title":"Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration","volume":"155","author":"Suffredini","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib282","first-page":"31","article-title":"Effects of infliximab treatment on rheumatoid synovial tissue","volume":"74","author":"Tak","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib283","series-title":"Apoptosis and Inflammation (Progress in Inflammation Research)","first-page":"149","article-title":"Apoptosis in rheumatoid arthritis","author":"Tak","year":"1999"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib285","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/art.1780400206","article-title":"Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity","volume":"40","author":"Tak","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib284","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/art.1780390702","article-title":"Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis","volume":"39","author":"Tak","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib286","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W","article-title":"Involvement of receptor activator of nuclear factor \u03baB ligand\/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis","volume":"43","author":"Takayanagi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib287","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4049\/jimmunol.167.2.1072","article-title":"Lymphoid neogenesis in rheumatoid synovitis","volume":"167","author":"Takemura","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib288","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2174\/1381612053381918","article-title":"Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy","volume":"11","author":"Tas","year":"2005","journal-title":"Curr Pharm Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib289","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L","article-title":"Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis","volume":"43","author":"Taylor","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib290","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","article-title":"Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease","volume":"50","author":"ten Hove","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib291","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/ard.62.2.178","article-title":"Effects of treatment with etanercept (Enbrel, TNRF:Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography","volume":"62","author":"Terslev","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib292","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1073\/pnas.89.16.7375","article-title":"Involvement of endogeneous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice","volume":"89","author":"Thorbecke","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib293","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/art.21266","article-title":"Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents","volume":"52","author":"Tutuncu","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib294","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.54.8.654","article-title":"Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis","volume":"54","author":"Ulfgren","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib295","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F","article-title":"Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis","volume":"43","author":"Ulfgren","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib296","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib297","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2005-11-4567","article-title":"TNF downmodulates the function of human CD4+CD25hi T-regulatory cells","volume":"108","author":"Valencia","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib298","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib299","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/ard.2006.057406","article-title":"Imaging and serum analysis of immune complex formation of radiolabeled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis","volume":"66","author":"van der Laken","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib300","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.40.4.443","article-title":"Tumour necrosis factor and Crohn's disease","volume":"40","author":"Van Deventer","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib301","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/ard.2006.057471","article-title":"TLR-4 Induced Fc\u03b3R expression potentiates early onset of joint inflammation and cartilage destruction during immune complex arthritis: tlr4 largely regulates Fc\u03b3R expression by IL-10","volume":"66","author":"van Lent","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib302","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/ard.2004.023259","article-title":"Inhibition of TNFalpha during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNFalpha blockade in rheumatoid arthritis","volume":"64","author":"van Lieshout","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib303","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/ard.2003.009589","article-title":"Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense","volume":"62","author":"van Vollenhoven","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib304","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1365-2249.2005.02859.x","article-title":"Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis","volume":"141","author":"Vigna-P\u00e9rez","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib305","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/ard.2005.044198","article-title":"Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NF\u03baB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis","volume":"65","author":"Vis","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib306","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.4049\/jimmunol.172.7.4332","article-title":"TNF and phorbol esters induce lymphotoxin-beta expression through distinct pathways involving Ets and NF-kappaB family members","volume":"172","author":"Voon","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib307","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.0105-2896.2005.00338.x","article-title":"Rheumatic diseases: the effects of inflammation on bone","volume":"208","author":"Walsh","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib308","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev.immunol.23.021704.115719","article-title":"Network communications: lymphotoxins, LIGHT, and TNF","volume":"23","author":"Ware","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib309","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.4049\/jimmunol.149.12.3881","article-title":"Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells","volume":"149","author":"Ware","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib310","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00007890-199702270-00015","article-title":"Biological effects and fate of a soluble, dimeric, 80-Kda tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy 1","volume":"63","author":"Wee","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib311","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib312","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib313","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib314","first-page":"535","article-title":"A new generation of high-affinity humanized PEGylated Fab' fragment anti-tumor necrosis factor-(alpha) monoclonal antibodies","volume":"3","author":"Weir","year":"2006","journal-title":"Therapy"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib315","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0149-2918(03)80164-9","article-title":"Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study","volume":"25","author":"Weisman","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib316","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/ar1737","article-title":"B cells in rheumatoid synovitis","volume":"7","author":"Weyand","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib317","doi-asserted-by":"crossref","first-page":"9784","DOI":"10.1073\/pnas.89.20.9784","article-title":"Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis","volume":"89","author":"Williams","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib318","doi-asserted-by":"crossref","first-page":"19451","DOI":"10.1074\/jbc.272.31.19451","article-title":"The lymphotoxin-alpha (LTalpha) subunit is essential for the assembly, but not for the receptor specificity, of the membrane-anchored LTalpha 1beta 2 heterotrimeric ligand","volume":"272","author":"Williams-Abbott","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib319","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib320","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib321","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.4049\/jimmunol.166.3.1684","article-title":"Signal via lymphotoxin-betaR on bone marrow stromal cells is required for an early checkpoint of NK cell development","volume":"166","author":"Wu","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib322","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1084\/jem.180.3.995","article-title":"Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice.I. The early development of autoimmunity and the diabetogenic process","volume":"180","author":"Yang","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib323","doi-asserted-by":"crossref","first-page":"11846","DOI":"10.1074\/jbc.M512624200","article-title":"Tumor necrosis factor-\u03b1 increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression","volume":"281","author":"Yao","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib324","first-page":"893","article-title":"Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein","volume":"137","author":"Zeltser","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib325","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/0091270004273321","article-title":"Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein","volume":"45","author":"Zhou","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib326","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5414\/CPP42267","article-title":"Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis","volume":"42","author":"Zhou","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib327","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0091270006298188","article-title":"Pharmacokinetics and safety of golimumab, a fully human anti-TNF-a monoclonal antibody, in subjects with rheumatoid arthritis","volume":"47","author":"Zhou","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib328","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/art.10388","article-title":"High levels of osteoprotegerin and soluble receptor activator of nuclear factor B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor \u00e1 treatment","volume":"46","author":"Ziolkowska","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2007.10.001_bib329","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.11487","article-title":"Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction","volume":"50","author":"Zwerina","year":"2004","journal-title":"Arthritis Rheum"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725807002069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725807002069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T18:48:34Z","timestamp":1684090114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725807002069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":330,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0163725807002069"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2007.10.001","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}